Towards Healthcare
Next-Gen Proteomics Market Size, Drivers and Key Challenges

Next-Gen Proteomics Market Opportunities and Key Trends

The increasing demand for personalized medicine and drug discovery in proteomics is driving the market expansion. Whereas, North America was dominant in the market, due to growing chronic disease incidences and accelerating advancements in healthcare infrastructure, and a strong life sciences industry.

Content

  • Last Updated: 01 November 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The global next-gen proteomics market is being driven by a convergence of factors a surge in chronic diseases like cancer, cardiovascular, and autoimmune disorders

Asia Pacific is expected to grow at the fastest CAGR through 2034, fueled by rising healthcare expenditures, expanding R&D infrastructure, and a growing burden of chronic diseases.

Mass spectrometry leads in adoption due to its high precision in protein analysis, while protein microarrays are expected to see the fastest growth due to their utility in biomarker discovery and disease diagnostics

AI enables rapid and accurate interpretation of complex proteomics datasets, identifying biomarkers, predicting drug responses, and integrating multi-omics data.

High capital expenditure for advanced instruments, complex data analysis requiring skilled personnel, and limited accessibility in low-resource settings pose significant challenges.

Pharmaceutical and biotechnology companies are the dominant end-users due to their extensive drug discovery programs and precision medicine initiatives

Next-gen proteomics enables the identification and validation of protein targets, mechanism-of-action studies, and biomarker discovery, significantly shortening drug development timelines.
Any Questions